"Complement C5a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
| Descriptor ID |
D015936
|
| MeSH Number(s) |
D12.776.124.486.274.024.270 D12.776.124.486.274.450.250
|
| Concept/Terms |
Complement C5a- Complement C5a
- C5a, Complement
- C5a Complement
- Complement, C5a
- Complement Component 5a
- Component 5a, Complement
- Complement 5a
|
Below are MeSH descriptors whose meaning is more general than "Complement C5a".
Below are MeSH descriptors whose meaning is more specific than "Complement C5a".
This graph shows the total number of publications written about "Complement C5a" by people in this website by year, and whether "Complement C5a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2017 | 3 | 4 | 7 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 3 | 3 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C5a" by people in Profiles.
-
Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality. J Clin Immunol. 2021 10; 41(7):1607-1620.
-
Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol. 2021 07; 51(7):1652-1659.
-
[Involvement of the complement cascade in severe forms of COVID-19]. Med Sci (Paris). 2021 Apr; 37(4):333-341.
-
The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. Comput Biol Chem. 2021 Jun; 92:107482.
-
Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021 Apr; 82(4):264-269.
-
Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun. 2021 02; 117:102595.
-
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev. 2021 04; 58:75-81.
-
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol. 2020; 11:599417.
-
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends Immunol. 2020 11; 41(11):965-967.
-
COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020 09; 18(9):2110-2117.